Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$19.90
-1.2%
$22.09
$18.61
$47.00
$1.32B1.76864,209 shs9,414 shs
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
$3.36
$0.00
$2.47
$5.98
$344.00M2.351.69 million shs2.60 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$7.49
-0.9%
$8.21
$3.81
$23.86
$1.21B2.927.96 million shs40,270 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.78
-1.4%
$1.66
$0.99
$2.04
$1.19B1.74.20 million shs29,882 shs
7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-3.03%+1.31%-10.28%-19.82%-51.38%
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Novavax, Inc. stock logo
NVAX
Novavax
-1.69%-4.91%-5.38%-11.16%+57.17%
OPKO Health, Inc. stock logo
OPK
OPKO Health
-0.55%+0.56%+7.14%+19.21%+78.22%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
2.2741 of 5 stars
4.42.00.00.02.50.00.0
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
3.6937 of 5 stars
3.21.00.04.72.21.70.6
OPKO Health, Inc. stock logo
OPK
OPKO Health
4.2309 of 5 stars
3.50.00.04.43.85.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
2.89
Moderate Buy$54.33173.05% Upside
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
0.00
N/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
2.43
Hold$18.00140.32% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
3.00
Buy$2.7554.93% Upside

Current Analyst Ratings Breakdown

Latest KERX, CLDX, NVAX, and OPK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/20/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$46.00
3/19/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
3/12/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
3/12/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
3/3/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$42.00 ➝ $36.00
3/3/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
2/28/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
2/28/2025
Novavax, Inc. stock logo
NVAX
Novavax
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$19.00
2/28/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
2/27/2025
Novavax, Inc. stock logo
NVAX
Novavax
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
2/13/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$44.00
(Data available from 3/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$7.02M188.17N/AN/A$9.08 per share2.19
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
$60.64M5.67N/AN/A($0.12) per share-28.00
Novavax, Inc. stock logo
NVAX
Novavax
$682.16M1.77N/AN/A($6.04) per share-1.24
OPKO Health, Inc. stock logo
OPK
OPKO Health
$713.14M1.67N/AN/A$1.80 per share0.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$141.43M-$2.45N/AN/AN/A-1,544.32%-19.75%-18.86%5/5/2025 (Estimated)
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
-$163.44M-$0.88N/AN/AN/A-96.41%N/A-60.05%N/A
Novavax, Inc. stock logo
NVAX
Novavax
-$545.06M-$1.33N/A93.632.85-32.18%N/A-17.05%5/9/2025 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$188.86M-$0.09N/AN/AN/A-18.65%-9.76%-6.46%5/6/2025 (Estimated)

Latest KERX, CLDX, NVAX, and OPK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/27/2025Q4 2024
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$0.73-$0.71+$0.02-$0.71$1.25 million$1.18 million
2/27/2025Q4 24
Novavax, Inc. stock logo
NVAX
Novavax
-$0.75-$0.51+$0.24-$0.51$85.48 million$88.31 million
2/27/2025Q4 2024
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.08$0.01+$0.09$0.01$155.42 million$183.60 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/AN/AN/AN/AN/A
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
24.27
24.27
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
N/A
2.21
1.19
Novavax, Inc. stock logo
NVAX
Novavax
N/A
0.93
0.93
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.30
2.97
2.69

Institutional Ownership

CompanyInstitutional Ownership
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
69.00%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%

Insider Ownership

CompanyInsider Ownership
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
3.80%
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
1.61%
Novavax, Inc. stock logo
NVAX
Novavax
1.00%
OPKO Health, Inc. stock logo
OPK
OPKO Health
47.26%
CompanyEmployeesShares OutstandingFree FloatOptionable
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
15066.38 million63.82 millionOptionable
Keryx Biopharmaceuticals, Inc. stock logo
KERX
Keryx Biopharmaceuticals
N/A102.38 millionN/AOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990160.84 million158.58 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
3,930671.55 million359.94 millionOptionable

Recent News About These Companies

OPKO Health, Inc. stock logo
Zacks Research Weighs in on OPKO Health FY2027 Earnings
HC Wainwright Has Optimistic View of OPKO Health Q2 Earnings
Opko Health CEO buys $348K in common stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

Celldex Therapeutics stock logo

Celldex Therapeutics NASDAQ:CLDX

$19.90 -0.25 (-1.25%)
As of 09:54 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Keryx Biopharmaceuticals stock logo

Keryx Biopharmaceuticals NASDAQ:KERX

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.

Novavax stock logo

Novavax NASDAQ:NVAX

$7.49 -0.07 (-0.93%)
As of 09:54 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.78 -0.03 (-1.39%)
As of 09:54 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.